Spots Global Cancer Trial Database for solid tumor malignancy
Every month we try and update this database with for solid tumor malignancy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product | NCT05768269 | Hematological M... Solid Tumor Mal... | No Intervention | 18 Years - | Century Therapeutics, Inc. | |
| Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | NCT01012362 | Breast Cancer Lung Cancer Colon Cancer Pancreatic Canc... Head and Neck C... Kidney Cancer Sarcoma Hepatocellular ... | Pazopanib Ixabepilone | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) | NCT02186821 | Tumors With Abe... | Ceritinib | 18 Years - | Novartis | |
| Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC) | NCT00826449 | Lung Cancer Non-Small Cell ... | Dasatinib Erlotinib | 16 Years - | M.D. Anderson Cancer Center | |
| A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011) | NCT01254630 | Herpes Zoster | V212 Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors | NCT00528619 | Neoplasms | Sunitinib, Peme... | 18 Years - | Pfizer | |
| A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product | NCT05768269 | Hematological M... Solid Tumor Mal... | No Intervention | 18 Years - | Century Therapeutics, Inc. | |
| Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies | NCT01611623 | Cancer | SNX-5422 | 18 Years - | Esanex Inc. | |
| Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas | NCT00647764 | Solid Tumor Mal... Lymphoid Malign... Leukemia Lymphoma | SNX-5422 Mesyla... | 18 Years - | Esanex Inc. | |
| Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors | NCT01343498 | Malignant Solid... | BEZ235 | 18 Years - | SCRI Development Innovations, LLC | |
| Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients | NCT05164016 | Cancer Hematopoietic S... Transplant-Rela... Solid Tumor Mal... Hematologic Mal... Solid Organ Tra... Hematopoietic C... Cellular Therap... | - 24 Years | St. Jude Children's Research Hospital | ||
| Selinexor Combination Ph 1 Study | NCT05177276 | Solid Tumor Mal... | Selinexor Irinotecan | 18 Years - | Hackensack Meridian Health | |
| Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) | NCT03822117 | Solid Tumor Mal... | Pemigatinib | 18 Years - | Incyte Corporation | |
| Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib | NCT01831726 | Tumor Pathway A... | Dovitinib (TKI2... | 18 Years - 100 Years | Novartis | |
| Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients | NCT05164016 | Cancer Hematopoietic S... Transplant-Rela... Solid Tumor Mal... Hematologic Mal... Solid Organ Tra... Hematopoietic C... Cellular Therap... | - 24 Years | St. Jude Children's Research Hospital | ||
| BGJ398 for Patients With Tumors With FGFR Genetic Alterations | NCT02160041 | Solid Tumor Hematologic Mal... | BGJ398 | 18 Years - | Novartis | |
| Single Versus Multifraction Salvage Spine Stereotactic Radiosurgery for Previously Irradiated Spinal Metastases | NCT03028337 | Malignant Neopl... | Spine Radiosurg... Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011) | NCT01254630 | Herpes Zoster | V212 Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC) | NCT00826449 | Lung Cancer Non-Small Cell ... | Dasatinib Erlotinib | 16 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) | NCT03822117 | Solid Tumor Mal... | Pemigatinib | 18 Years - | Incyte Corporation | |
| A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Boost... | NCT04847050 | Solid Tumor Mal... Hematologic Mal... Leukemia Lymphoma Multiple Myelom... | mRNA-1273 | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
